List of Excipients in Branded Drug PROCHLORPERAZINE MALEATE

« Back to Dashboard

Generic Drugs Containing PROCHLORPERAZINE MALEATE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	prochlorperazine maleate	0378-5105	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	prochlorperazine maleate	0378-5105	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	prochlorperazine maleate	0378-5105	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	prochlorperazine maleate	0378-5105	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in PROCHLORPERAZINE MALEATE?

# Of NDCs	Excipient
1	ALUMINA
28	ALUMINUM OXIDE
65	CELLULOSE, MICROCRYSTALLINE
10	CROSCARMELLOSE SODIUM

Prochlorperazine Maleate Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Prochlorperazine maleate is an established generic phenothiazine used primarily for severe nausea and vomiting and, in some markets, schizophrenia and other psychotic disorders. Its commercial value is driven by manufacturing efficiency, product differentiation, supply reliability, and formulation performance rather than new-molecule exclusivity. The strongest opportunities are low-cost immediate-release tablets, orally disintegrating or rapidly dispersing products, taste-masked dosage forms, and institutionally focused products with improved packaging and supply continuity.

What is the regulatory status of prochlorperazine maleate?

Prochlorperazine maleate is a small-molecule prescription drug. FDA-approved dosage forms have included oral tablets, while prochlorperazine edisylate is used for injectable products. The maleate salt is not a biologic and does not create biosimilar exposure. Generic approval generally proceeds through an abbreviated new drug application, subject to reference-product requirements and applicable bioequivalence standards.

Attribute	Prochlorperazine maleate
Drug class	Phenothiazine antiemetic and antipsychotic
Primary oral use	Severe nausea and vomiting
Common oral strengths	5 mg and 10 mg
Dosage form	Immediate-release tablet
Regulatory pathway	ANDA for generic products
Biosimilar risk	None
Main commercial reference	Compazine and generic equivalents
Key technical issues	Low-dose content uniformity, taste, powder flow, tablet robustness, moisture and light control
Patent position	Mature generic market with limited practical value from legacy molecule patents

FDA product-specific guidance, labeling databases, and the Orange Book should be reviewed for the current reference-listed drug, dosage form, strength, therapeutic-equivalence code, and any active patents or exclusivity listings.[1-3]

What excipients are used in prochlorperazine maleate tablets?

Excipient composition varies by manufacturer, strength, coating system, and manufacturing process. Common excipient classes include fillers, binders, disintegrants, glidants, lubricants, pigments, and film-coating polymers.

Typical excipient architecture

Functional role	Common candidates	Relevance to prochlorperazine maleate
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate, mannitol	Supports tablet mass and content uniformity at the 5 mg and 10 mg strengths
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Controls granule strength and reduces segregation
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Supports immediate release and rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and tooling adhesion
Glidant	Colloidal silicon dioxide, talc	Improves flow and die filling
Coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves swallowability, appearance, light protection, and product identification
Sweetener or flavor system	Sucralose, saccharin sodium, mannitol, flavors	Relevant to orally disintegrating, chewable, or liquid products
pH modifier	Citrate, phosphate, or other pharmaceutically acceptable buffers	More relevant to liquid and orally dispersible systems

The FDA Inactive Ingredient Database should be used to screen prior human exposure by route, dosage form, and maximum potency before selecting a new excipient system.[4] Excipient selection must also comply with the applicable USP-NF monographs and current regulatory expectations for elemental impurities, residual solvents, microbial quality, and nitrosamine risk.[5-8]

How should an excipient strategy address prochlorperazine maleate?

The formulation target should be a robust immediate-release product with consistent low-dose uniformity, acceptable disintegration, stable assay, and low manufacturing cost. The salt form and the relatively small drug load make blend uniformity and segregation important process risks.

1. Control low-dose content uniformity

At 5 mg, prochlorperazine maleate represents a small fraction of total tablet weight. Direct compression can be commercially attractive but may create segregation risk if the active pharmaceutical ingredient and excipients differ substantially in particle size, density, or morphology.

A practical strategy is:

• Use a narrow particle-size distribution for the active ingredient.
• Match active and excipient density where possible.
• Apply ordered mixing or geometric dilution.
• Consider dry granulation or wet granulation if direct compression fails blend-uniformity targets.
• Establish blend-sampling plans that reflect the actual equipment and scale.
• Control lubricant addition time because over-lubrication can reduce tablet strength and slow disintegration.

Microcrystalline cellulose, pregelatinized starch, and low-substituted hydroxypropyl cellulose can support direct compression and rapid breakup. Lactose-based systems may reduce cost but require control of moisture, grade selection, and compatibility.

2. Manage taste and mouthfeel

Prochlorperazine products can present a bitter or unpleasant taste challenge. Conventional swallowed tablets can use a film coat to reduce contact with taste receptors. A rapidly disintegrating or orally disintegrating product requires stronger taste-masking control.

Potential approaches include:

• Polymer film coating.
• Drug layering onto a particulate carrier.
• Ion-exchange resin complexation.
• Lipid or polymeric microencapsulation.
• pH-modified granules.
• Sweetener and flavor systems used with a compatible saliva-dispersing matrix.

Taste masking must not materially delay dissolution or produce an inconsistent dose. Resin complexes and insoluble coatings can create dissolution risk if the product is intended to achieve rapid systemic exposure.

3. Optimize disintegration without compromising strength

For an immediate-release tablet, crospovidone, croscarmellose sodium, or sodium starch glycolate can provide rapid disintegration. The preferred disintegrant depends on compression force, tablet porosity, granulation method, and lubricant concentration.

A dual-disintegrant system can improve robustness, but unnecessary excipient complexity increases cost and regulatory burden. The development target should be the fastest reliable disintegration profile that remains compatible with mechanical strength, friability, packaging, and dissolution requirements.

4. Address moisture and light exposure

The selected formulation should be assessed for:

• Moisture-driven potency loss or degradation.
• Tablet softening or swelling.
• Coating defects.
• Photostability.
• Interaction with hygroscopic excipients.
• Stability after removal from the primary package.

Opaque high-density polyethylene bottles with desiccant, aluminum-aluminum blister packs, and high-barrier PVC/PVdC systems are potential packaging options. The optimal package depends on stability data, distribution conditions, unit-dose requirements, and cost targets.

What formulations are protected by prochlorperazine maleate patents?

The commercial market is primarily composed of legacy immediate-release products. New commercial value is more likely to come from formulation engineering than from the original active ingredient.

Formulation concept	Commercial rationale	Main technical barrier
Standard 5 mg and 10 mg tablet	Lowest development and manufacturing cost	Price competition and limited differentiation
Film-coated tablet	Better swallowability, branding, light control	Coating cost and dissolution impact
Orally disintegrating tablet	Useful for nausea patients who cannot swallow conventional tablets	Taste masking, friability, moisture sensitivity
Chewable tablet	Administration convenience	Taste and dose uniformity
Oral solution or suspension	Flexible dosing and pediatric or institutional use	Chemical stability, microbial control, packaging
Unit-dose blister	Hospital, emergency, and travel use	Packaging cost and line compatibility
Combination product	Potential adherence or symptom-management positioning	Regulatory complexity and limited market size

Any patentability would generally depend on a novel composition, manufacturing process, delivery system, or clinically meaningful performance advantage. A conventional tablet containing standard excipients is unlikely to create a durable patent position unless the formulation produces an unexpected technical result.

When does prochlorperazine maleate lose exclusivity?

Prochlorperazine maleate is a mature generic product. The original compound and early product patents are historical rather than commercially relevant to current generic entry. Current exclusivity analysis should focus on the specific FDA reference product and any active listed patents in the Orange Book, not on the original launch date alone.[2,3]

There is no biosimilar exclusivity issue because prochlorperazine maleate is a chemically synthesized small molecule. Any market-entry barrier is more likely to arise from:

• ANDA approval timing.
• Paragraph IV certification.
• Product-specific litigation.
• Controlled manufacturing capacity.
• Supply-chain qualification.
• Formulation or process patents covering a differentiated product.
• State or hospital purchasing contracts.

The current patent and exclusivity status must be verified against the latest Orange Book and FDA patent-listing data before a launch decision.

How many patents cover prochlorperazine maleate?

A meaningful patent count depends on the specific dosage form, manufacturer, and jurisdiction. Legacy composition-of-matter patents are generally expired because prochlorperazine was developed decades ago. The relevant commercial question is whether any active patents cover a current reference-listed product or a differentiated formulation.

For standard immediate-release prochlorperazine maleate tablets, the practical patent estate is generally weak compared with newer branded drugs. A company seeking entry should prioritize:

1. Orange Book-listed patents for the selected reference product.
2. U.S. patent applications and grants covering orally disintegrating systems.
3. Taste-masking and multiparticulate technologies.
4. Manufacturing processes that produce a distinct crystalline, granulated, or coated form.
5. Foreign patents in markets where generic substitution is commercially attractive.

Patent screening should include the United States, European Patent Office, United Kingdom, Canada, Australia, Japan, and major emerging markets. National-phase status, maintenance fees, terminal disclaimers, and claim scope are more important than raw patent-family counts.

What is the Orange Book status of prochlorperazine maleate?

The Orange Book determines whether a listed product has therapeutic-equivalence information and whether patents or regulatory exclusivities are recorded for the reference product.[2] Generic applicants should confirm:

• The active ingredient and salt designation.
• The approved strength and dosage form.
• The reference-listed drug.
• The therapeutic-equivalence code.
• Any patent-use code.
• Any active regulatory exclusivity.
• Whether the proposed product can rely on a same-label pathway or requires a suitability petition or other regulatory strategy.

Paragraph IV risk is usually limited for a mature generic unless an active formulation or method-of-use patent remains listed. A Paragraph IV certification can create litigation exposure, but it may also provide a route to earlier market entry where the listed patent is weak, expired, or vulnerable to invalidity or noninfringement arguments.

What generic entry risks exist for prochlorperazine maleate?

The principal risks are commercial and operational rather than molecule-level patent risks.

Competitive pricing

Multiple suppliers can compress pricing for standard tablets. A new entrant needs a cost advantage, reliable supply, a differentiated pack, or a customer segment that values continuity over the lowest unit price.

Manufacturing economics

The active dose is low, so process yield and batch-size economics matter. Packaging, testing, and quality-release costs can represent a material share of total cost of goods.

Quality and supply continuity

Phenothiazine products may face customer sensitivity to discoloration, tablet defects, assay drift, and dissolution variability. A supplier with dual-source excipients, validated alternate manufacturing sites, and strong change-control systems can compete for hospital and wholesaler contracts.

Label and safety constraints

Prochlorperazine carries clinically important warnings associated with phenothiazine therapy, including extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, and other serious adverse reactions.[9] These risks constrain promotional positioning and favor clear labeling, medication guides where applicable, and disciplined pharmacovigilance.

Which commercial opportunities are strongest?

Orally disintegrating and rapidly dispersing tablets

Patients receiving antiemetic treatment may have difficulty swallowing. A rapidly dispersing product could compete on administration convenience, but commercial success depends on effective taste masking and a stable, low-cost package.

Institutional and emergency-care packaging

Unit-dose blister packs, barcode-ready cartons, and tamper-evident packaging may appeal to hospitals, emergency departments, long-term-care facilities, and correctional-health systems. The opportunity is operational rather than patent-led.

Supply-reliable standard tablets

A manufacturer can win share through dual sourcing, short lead times, and consistent allocation during shortages. For a mature generic, supply continuity can be more valuable than a minor formulation improvement.

Pediatric and flexible-dose products

An oral liquid or dispersible dosage form could support patients unable to swallow tablets. The principal barriers are stability, preservative selection, microbial control, dosing-device accuracy, and taste.

Geographic expansion

Markets with limited generic competition may offer better margins than the United States, especially where oral antiemetic products are supplied through hospitals or national tenders. Registration requirements, local patent status, pharmacopoeial standards, and procurement rules differ by jurisdiction.

How does prochlorperazine maleate compare with competing antiemetics?

Product	Main dosage-form opportunity	Excipient and commercial angle
Prochlorperazine maleate	Low-cost tablet, ODT, liquid	Taste masking, low-dose uniformity, institutional supply
Ondansetron	Tablet, ODT, oral solution	Strong ODT competition and established antiemetic demand
Promethazine	Tablet, syrup, suppository, injection	Liquid and pediatric formulation experience; safety restrictions
Metoclopramide	Tablet, liquid, injection	Broad generic competition and neurologic safety considerations
Dimenhydrinate	Tablet, chewable, liquid	OTC-style convenience and taste-driven differentiation

Prochlorperazine is most competitive where low acquisition cost, established clinical familiarity, and multiple dosage-form options matter. Ondansetron generally has stronger commercial recognition in modern antiemetic prescribing, while prochlorperazine may compete in cost-sensitive and institutional channels.

What licensing deals and litigation affect prochlorperazine maleate?

No molecule-level licensing opportunity is necessary for a standard generic product because the active ingredient is long established. Licensing may be relevant for:

• Taste-masking technology.
• Orally disintegrating tablet platforms.
• Multiparticulate coating systems.
• Unit-dose packaging.
• Contract manufacturing.
• Regional commercialization rights.

Litigation exposure should be assessed at the product and formulation level. Relevant cases may involve Paragraph IV certifications, ANDA filing disputes, formulation patents, or contractual supply issues. A current litigation search is required before relying on any specific case, settlement, or launch date. Standard product development should not assume that a historical patent dispute remains active.

How strong is the patent estate for prochlorperazine maleate?

The patent estate for conventional prochlorperazine maleate tablets is commercially weak because the active ingredient is old and generic competition is established. The strongest defensible positions are likely to be narrow formulation or process claims supported by comparative data.

A stronger strategy would require evidence of:

• Faster disintegration without impaired dissolution.
• Improved taste scores.
• Better stability under accelerated conditions.
• Reduced tablet weight or improved swallowability.
• Lower batch-failure rates.
• Improved bioavailability or reduced variability.
• A manufacturing process that materially lowers cost.

Patent claims should be paired with trade secrets covering granulation parameters, coating conditions, blend order, compression settings, and analytical controls. A formulation patent alone may not prevent competition if a rival can design around the claim.

Key Takeaways

• Prochlorperazine maleate is a mature small-molecule generic with no biosimilar risk.
• Standard tablets are likely to face substantial price competition.
• The most attractive excipient strategy emphasizes low-dose content uniformity, rapid disintegration, taste control, and stable packaging.
• Orally disintegrating, rapidly dispersing, liquid, and unit-dose products offer the clearest differentiation opportunities.
• Patent value is likely to reside in novel formulation or manufacturing claims, not in the active ingredient.
• Orange Book review, Paragraph IV analysis, and current litigation screening are required before a specific launch or settlement conclusion.
• Commercial advantage is more likely to come from supply reliability, institutional packaging, and efficient manufacturing than from exclusivity.

FAQs

Is prochlorperazine maleate suitable for an orally disintegrating tablet?

Yes, but the product requires effective taste masking, rapid dispersion, low friability, moisture-protective packaging, and dissolution performance consistent with an immediate-release product.

Which excipient is best for prochlorperazine maleate tablets?

No single excipient is universally optimal. Microcrystalline cellulose, crospovidone, croscarmellose sodium, pregelatinized starch, lactose, and mannitol are candidate materials whose suitability depends on the manufacturing process and target dosage form.

Can prochlorperazine maleate be formulated as an oral liquid?

Yes. The formulation must address salt solubility, chemical stability, microbial preservation, dose-measuring accuracy, palatability, and container compatibility.

Does prochlorperazine maleate have meaningful biosimilar competition?

No. It is a chemically synthesized small molecule approved through conventional generic-drug pathways, not a biologic subject to biosimilar competition.

Is a new prochlorperazine maleate formulation likely to receive patent protection?

Patent protection is possible for a genuinely novel composition, delivery system, manufacturing process, or demonstrated performance advantage. A conventional tablet using standard excipients is unlikely to create a strong standalone patent position.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
3. U.S. Food and Drug Administration. (n.d.). Patent listings and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-content-and-format
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary, USP 47-NF 42.
6. International Council for Harmonisation. (2023). ICH Q8(R2): Pharmaceutical development.
7. International Council for Harmonisation. (2023). ICH Q9(R1): Quality risk management.
8. International Council for Harmonisation. (2023). ICH Q10: Pharmaceutical quality system.
9. National Library of Medicine. (n.d.). DailyMed: Prochlorperazine maleate prescribing information. https://dailymed.nlm.nih.gov/dailymed/